[1]傅文霞 乐佳玮 李若谷.完全性左束支阻滞的冠心病患者中合并心功能不全的相关危险因素分析[J].心血管病学进展,2020,(12):1310-1314.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
　FU Wenxia,LE Jiawei,LI Ruogu.Analysis of Risk Factors for Cardiac Dysfunction in Patients with Coronary Heart Disease Complicated with Complete Left Bundle Branch Block[J].Advances in Cardiovascular Diseases,2020,(12):1310-1314.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
点击复制

完全性左束支阻滞的冠心病患者中合并心功能不全的相关危险因素分析()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年12期
页码:
1310-1314
栏目:
论著
出版日期:
2020-12-25

文章信息/Info

Title:
Analysis of Risk Factors for Cardiac Dysfunction in Patients with Coronary Heart Disease Complicated with Complete Left Bundle Branch Block
作者:
傅文霞1 乐佳玮1 李若谷1; 2
(1.上海交通大学附属胸科医院 上海市胸科医院心功能室,上海 200030;2. 上海交通大学附属胸科医院 上海市胸科医院心内科,上海 200030)
Author(s):
FU Wenxia1;  LE Jiawei1;  LI Ruogu1; 2
(1.Cardiac Function Room,Shanghai Chest Hospital,Shanghai Chest Hospital Shanghai Jiaotong University,Shanghai 200030,China;2.Department of Cardiology,Shanghai Chest Hospital,Shanghai Chest Hospital Shanghai Jiaotong University,Shanghai 200030,China)
关键词:
完全性左束支传导阻滞; 冠心病; 危险因素; 心功能不全
Keywords:
Complete left bundle branch block;  Coronary heart disease;  Risk factors;  Cardiac dysfunction
DOI:
10.16806/j.cnki.issn.1004-3934.2020.12.021
摘要:
目的 探讨完全性左束支阻滞的冠心病患者中合并心功能不全的相关危险因素分析。方法 2016年6月—2020年3月因疑诊或确诊冠心病连续就诊于上海市胸科医院心内科，行选择性冠状动脉造影术及心电图诊断完全性左束支阻滞患者147例，最终入选冠心病（冠状动脉狭窄≥50%）且心电图诊断完全性左束支阻滞患者80例。根据是否发生心功能不全分成两组，同时进行单因素及多因素logistic回归分析合并心功能不全的相关因素。结果（1）2组间高血压、陈旧性心肌梗死和冠状动脉多支病变比例差异均有统计学意义（P均＜0.05），且冠状动脉狭窄程度高于无心功能不全组（P=0.014）；心率、脑钠肽、肌酐水平差异均有统计学意义（P均＜0.05）。住院期间用药、服用β受体阻滞剂、钙通道阻滞剂、利尿剂和螺内酯比例明显高于无心功能不全组（P均＜0.05）。住院期间合并心功能不全组发生主要不良心血管事件高于无心功能不全组（P=0.017）。（2）合并心功能不全组左室收缩末期内径、左室舒张末期内径、左室舒张末期容积和E/E’峰比值高于无合并心功能不全组（P均＜0.05）。合并心功能不全组左室短轴缩短率、左室射血分数低于无合并心功能不全组（P均＜0.05）。心电图结果显示，合并心功能不全组校正的QT间期高于无合并心功能不全组（P＜0.05）。（3）单因素及多因素logistic回归分析：高血压、肌酐是合并心功能不全的独立相关危险因素。结论 除了常规脑钠肽升高，对于心电图提示校正的QT间期延长，具有高血压病史，肌酐升高的冠心病患者，也应该引起重视与关注。定期观察和长期随访，若出现异常升高，尽早进行就诊，防止心功能进一步恶化。
Abstract:
Objective To investigate risk factors for cardiac dysfunction in patients with coronary heart disease (CAD) complicated with complete left bundle branch block (CLBBB). Methods 147 patients with CLBBB underwent selective coronary angiography and electrocardiogram , and consecutively hospitalized in Department of Cardiology of Shanghai Chest Hospital for suspected or diagnosed with CAD from June 2016 to March 2020 were initially selected , of whom 80 cases diagnosed with CAD (coronary artery stenosis≥50%) complicated with CLBBB were finally enrolled, and classified into non-cardiac and cardiac insufficiency group based on cardiac functions. Associated risk factors for cardiac insufficiency were analyzed by univariate and multivariate logistic regression. Results (1) There were significant differences between two groups in hypertension , prior myocardial infarction and multivessel diseases ( P＜0.05 each ). The degree of coronary stenosis was higher in cardiac insufficiency group than non-cardiac (P=0.014). Heart rate, brain natriuretic peptide (BNP) and creatinine levels were statistically significant (P＜0.05 each ). Compared to non-cardiac insufficiency group, proportions of medications during hospitalization ,β-blockers, calcium channel blockers , diuretics and spironolactone were increased in cardiac insufficiency group (P＜0.05 each),and the major adverse cardiovascular events during hospitalization were increased as well (P=0.017). (2) The left ventricular end-systolic diameter, left ventricular end-diastolic diameter and volume , E/E’ peak ratio were higher in cardiac insufficiency group than non-cardiac (P＜0.05 each ). The FS and LVEF were lower than in cardiac insufficiency group than non-cardiac (P<0.05 each ). ECG results showed that the QTC duration was higher in cardiac insufficiency group (P＜0.05). (3) Univariate and multivariate logistic regression analysis showed hypertension and creatinine were independent risk factors for cardiac insufficiency in patients with CAD complicated with CLBBB. Conclusions Besides increased routine BNP , prolonged QTC duration in electrocardiogram , previous hypertension and elevated creatinine in patients with CAD complicated with CLBBB deserve more attentions and concerns. Regular observation and long-term follow-up is necessary. Once abnormal elevations were found , seeking for early medical advice was recommended to prevent further deterioration of cardiac function.

参考文献/References:

[1]Deniz A,Ozmen C,Aktas H,et al. Electrocardiographic markers of left ventricular systolic dysfunction in patients with left bundle branch block[J]. Kardiol Pol,2016,74(1):25-31.

[2]Vernooy K,Verbeek XA,Peschar M,et al. Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion[J]. Eur Heart J,2005,26(1):91-98.

[3]Wang JG,Fang W,Yang MF,et al. Septal and anterior reverse mismatch of myocardial perfusion and metabolism in patients with coronary artery disease and left bundle branch block[J]. Medicine (Baltimore),2015,94(20)e772.

[4]Eriksson P,Wilhelmsen L,Rosengren A. Bundle-branch block in middle-aged men:risk of complications and death over 28 years. The primary prevention study in G?teborg,Sweden[J]. Eur Heart J,2005,26(21):2300-2306.

[5]Masci PG,Marinelli M,Piacenti M,et al.Myocardial structural,perfusion,and metabolic correlates of left bundle branch block mechanical derangement in patients with dilated cardiomyopathy:a tagged cardiac magnetic resonance and positron emission tomography study[J].Circ Cardiovasc Imaging,2010,3(4):482-490.

[6]Nowak B,Sinha AM,Schaefer WM,et al.Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block[J].J Am Coll Cardiol,2003,41(9):1523-1528.

[7]Li Z,Dahl?f B,Okin PM,et al. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy:the losartan intervention for endpoint reduction in hypertension study[J]. J Hypertens,2008,26(6):1244-1249.

[8]Abrol R,Trost,JC,Nguyen K,et al. Predictors of coronary artery disease in patients with left bundle branch block undergoing coronary angiography[J]. Am J Cardiol,2006,98(10):1307-1310.

[9]Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200.

[10]赵磊,张鹏飞,张鹏翔,等. 血浆B型脑钠肽在不同病因及类型心力衰竭中的变化及意义[J]. 中国医科大学学报,2013,42(12):1079-1082.

[11]Yamaguchi H,Yoshida J,Yamamoto K,et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy[J]. J Am Coll Cardiol,2004,43(1):55-60 .

[12]胡盛寿,高润霖,刘力生,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019,34 (6):209-220.

[13]Bavelaar-Croon CD,Wahba FF,van Hecke MV,et al. Perfusion and functional abnormalities outside the septal region in patients with left bundle branch block assessed with gated SPECT[J]. Q J Nucl Med,2001,45(1):108-114.

[14] Badano LP,Gaddi O,Peraldo C,et al. Left ventricular electro-mechanical delay in patients with heart failure and normal QRS duration and in patients with right and left bundle branch block[J]. Europace,2007,9:41-47.

[15] Devkota A,Bakhit A,Dufresne A,et al. Arrhythmias and electrocardiographic changes in systolic heart failure[J]. N Am J Med Sci,2016,8(4):171-174.

[16] Vrtovec B, Knezevic I, Poglajen G,?et al. Relation of B-type natriuretic peptide level in heart failure to sudden cardiac death in patients with and without QT interval prolongation[J]. Am J Cardiol,2013,116(6):886-890.

[17] Richards AM,Frampton CM. N-terminal-pro-B-type natriuretic peptide:universal marker of cardiovascular risk?[J]. Circulation,2005,112(1):9-11.

[18] Brisco MA,Zile MR,Ter Maaten JM,et al. The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ration[J]. Int J Cardiol,2016,215:521-526.

[19] Kajimoto K,Minami Y,Sato N,et al. Serum sodium concentration,blood urea nitrogen,and outcomes in patients hospitalized for acute decompensated heart failure[J]. Int J Cardiol,2016,222:195-201.

相似文献/References:

[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
　DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
　NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
　LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(12):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
　YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
　SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(12):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
　GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(12):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
　DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(12):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
　CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(12):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
　YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
　GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(12):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]

备注/Memo

备注/Memo:
通信作者：李若谷，E-mail:liruogu1234@163.com
收稿时间：2020-07-31
更新日期/Last Update: 2021-02-22